In fact, KIT D816V mutation is found in 95% of SM patients and results in constitutive activation of the KIT receptor tyrosine kinase, driving mast cell growth, survival, and activation, contributing to the pathogenesis of SM [9]. Here, NTRK1 is linked to systemic mastocytosis.